In myelodysplastic syndrome, a recent report found significant responses to the combination of a DNMT1 inhibitor and a PDL1 inhibitor in some patients previously resistant to hypomethylating drugs [38]. Here, DNMT1 is linked to myelodysplastic syndrome.